In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cyberonics and Depression's Happy Face

Executive Summary

Seven years ago, Cyberonics was all but dead, with an interesting technology and little else. Left at the altar when St. Jude refused to exercise an option to buy the company, Cyberonics faced the daunting task of getting FDA approval for a novel approach to epilepsy therapy and convincing a conservative customer group, neurologists, of the value of its vagus nerve stimuation (VNS) therapy. But Cyberonics was able to establish VNS in epilepsy and the company is now targeting depression, a market that could be as much as ten times larger than its first indication. And as Cyberonics' prospects brighten, the company now faces the challenge of keeping would-be acquirers at bay.

Related Content

Neuronetics' FDA Nod Opens Doors to New CNS Market
Seizure Desist: Neurostim Companies Pursue Alternative Treatments for Epilepsy
Neurostimulation Market Expanding
Neuromodulation: Devices's Stimulating Growth Market
Cyberonics' Two-Front War
Northstar's Buzz
Neuronetics Inc.
Cyberonics Stumbles and ANS Lends a Hand
ANS Goes Along For The Ride
Cyberonics On Its Own


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts